Corvus Pharmaceuticals Valuation
Is CRVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CRVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRVS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRVS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRVS?
Key metric: As CRVS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is CRVS's PB Ratio? | |
|---|---|
| PB Ratio | 45.1x |
| Book | US$12.41m |
| Market Cap | US$515.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -19x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CRVS's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
GRAL GRAIL | 0.2x | 35.7% | US$507.0m |
ORGO Organogenesis Holdings | 1.9x | 123.3% | US$526.3m |
CELC Celcuity | 3.2x | 27.6% | US$474.5m |
GLUE Monte Rosa Therapeutics | 2.5x | 20.1% | US$513.6m |
CRVS Corvus Pharmaceuticals | 45.1x | 12.1% | US$515.4m |
Price-To-Book vs Peers: CRVS is expensive based on its Price-To-Book Ratio (45.1x) compared to the peer average (1.9x).
Price to Book Ratio vs Industry
How does CRVS's PB Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CRVS is expensive based on its Price-To-Book Ratio (45.1x) compared to the US Biotechs industry average (1.8x).
Price to Book Ratio vs Fair Ratio
What is CRVS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 45.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CRVS's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$8.94 | US$15.75 +76.2% | 30.6% | US$24.00 | US$12.00 | n/a | 4 |
| Nov ’25 | US$9.10 | US$12.25 +34.6% | 43.3% | US$21.00 | US$8.00 | n/a | 4 |
| Oct ’25 | US$5.09 | US$10.13 +98.9% | 64.6% | US$21.00 | US$3.50 | n/a | 4 |
| Sep ’25 | US$4.48 | US$7.88 +75.8% | 38.2% | US$12.00 | US$3.50 | n/a | 4 |
| Aug ’25 | US$2.99 | US$7.83 +162.0% | 44.3% | US$12.00 | US$3.50 | n/a | 3 |
| Jul ’25 | US$1.85 | US$7.83 +323.4% | 44.3% | US$12.00 | US$3.50 | n/a | 3 |
| Jun ’25 | US$2.16 | US$7.83 +262.7% | 44.3% | US$12.00 | US$3.50 | n/a | 3 |
| May ’25 | US$1.61 | US$7.50 +365.8% | 46.5% | US$12.00 | US$3.50 | n/a | 3 |
| Apr ’25 | US$1.86 | US$7.50 +303.2% | 46.5% | US$12.00 | US$3.50 | n/a | 3 |
| Mar ’25 | US$2.18 | US$6.88 +215.4% | 50.0% | US$12.00 | US$3.50 | n/a | 4 |
| Feb ’25 | US$2.13 | US$6.88 +222.8% | 50.0% | US$12.00 | US$3.50 | n/a | 4 |
| Jan ’25 | US$1.76 | US$6.88 +290.6% | 50.0% | US$12.00 | US$3.50 | n/a | 4 |
| Dec ’24 | US$1.61 | US$7.10 +341.0% | 43.7% | US$12.00 | US$3.50 | n/a | 5 |
| Nov ’24 | US$1.18 | US$7.10 +501.7% | 43.7% | US$12.00 | US$3.50 | US$9.10 | 5 |
| Oct ’24 | US$1.46 | US$7.10 +386.3% | 43.7% | US$12.00 | US$3.50 | US$5.09 | 5 |
| Sep ’24 | US$2.13 | US$6.90 +223.9% | 44.5% | US$12.00 | US$3.50 | US$4.48 | 5 |
| Aug ’24 | US$2.24 | US$6.88 +206.9% | 50.0% | US$12.00 | US$3.50 | US$2.99 | 4 |
| Jul ’24 | US$2.29 | US$6.38 +178.4% | 42.7% | US$10.00 | US$3.50 | US$1.85 | 4 |
| Jun ’24 | US$3.24 | US$6.38 +96.8% | 42.7% | US$10.00 | US$3.50 | US$2.16 | 4 |
| May ’24 | US$1.11 | US$2.83 +155.3% | 22.0% | US$3.50 | US$2.00 | US$1.61 | 3 |
| Apr ’24 | US$0.91 | US$2.83 +211.4% | 22.0% | US$3.50 | US$2.00 | US$1.86 | 3 |
| Mar ’24 | US$0.72 | US$2.83 +293.5% | 22.0% | US$3.50 | US$2.00 | US$2.18 | 3 |
| Feb ’24 | US$0.83 | US$2.83 +243.2% | 22.0% | US$3.50 | US$2.00 | US$2.13 | 3 |
| Jan ’24 | US$0.85 | US$2.83 +233.3% | 22.0% | US$3.50 | US$2.00 | US$1.76 | 3 |
| Dec ’23 | US$0.97 | US$2.50 +157.1% | 28.3% | US$3.50 | US$2.00 | US$1.61 | 3 |
| Nov ’23 | US$0.86 | US$3.88 +349.7% | 36.9% | US$6.00 | US$2.00 | US$1.18 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.86
7D
-5.2%
1Y
8.0%
Teva Pharmaceutical Industries
US$19.3b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$17.08
7D
2.0%
1Y
80.5%
Collegium Pharmaceutical
US$967.5m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.41
7D
0.5%
1Y
17.1%